Novo Nordisk stopped supplying a well-known diabetes drug to Russia – Rosbalt

This material (information) was produced, distributed and (or) sent by a foreign agent of RS-Balt JSC or relates to the activities of a foreign agent of RS-Balt JSC. 18+

Novo Nordisk has stopped deliveries to Russia of Ozempic (semaglutide), a popular diabetes drug. Roszdravnadzor received the corresponding notice from the Danish manufacturer in November 2022, reports RBC with reference to information provided by the department.

Manufacturers are required by law to provide advance notice to the authorities when supplies of a drug are discontinued. Roszdravnadzor reported that Novo Nordisk complied with these conditions.

According to the marketing agency DSM Group, in 2021 Ozempik was sold in the state segment for 18.66 million rubles, through pharmacies – for 1.23 billion rubles, in 2022 in the state segment – for 581.58 million rubles, through pharmacies – by 2.2 billion rubles, the agency notes.

Source: Росбалт by

*The article has been translated based on the content of Росбалт by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!